12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Other News

iQur infectious news

iQur received €5 million ($6.6 million) in funding from the EU's Framework Programme 7 (FP7) to develop a universal influenza vaccine based on iQur's tandem core vaccine technology. iQur...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >